Terminal · Institutions
Every 13F-reported equity position this quarter, with its quarter-over-quarter change — each row traces back to the SEC filing.
Every 13F-reported equity position this quarter, with its quarter-over-quarter change — each row traces back to the SEC filing.
ARCH Venture Management, LLC (CIK 1274403) reported $1.10B across 12 reported positions in its SEC 13F filing for 2026-06-30. Largest positions: PBLS ($175.5M, 15.95%), BEAM ($155.8M, 14.16%), RAPP ($155.4M, 14.12%), SPTX ($136.6M, 12.42%), ERAS ($129.9M, 11.81%). Source: SEC Form 13F.
| Rank | Ticker | Company | Value | % Portfolio | Shares | Action |
|---|---|---|---|---|---|---|
| 1 | PBLS | PARABILIS MEDICINES INC | $175.5M | 15.95% | 6.4M | New |
| 2 | BEAM | BEAM THERAPEUTICS INC | $155.8M | 14.16% | 4.5M | Hold |
| 3 | RAPP | RAPPORT THERAPEUTICS INC | $155.4M | 14.12% | 3.7M | Hold |
| 4 | SPTX | SEAPORT THERAPEUTICS INC | $136.6M | 12.42% | 6.3M | New |
| 5 | ERAS | ERASCA INC | $129.9M | 11.81% | 7.1M | Hold |
| 6 | VIR | VIR BIOTECHNOLOGY INC | $129.4M | 11.76% | 12.7M | Trimmed |
| 7 | MAZE | MAZE THERAPEUTICS INC | $123.0M | 11.18% | 4.1M | Hold |
| 8 | LYEL | LYELL IMMUNOPHARMA INC | $45.5M | 4.14% | 3.2M | Hold |
| 9 | GENB | GENERATE BIOMEDICINES INC | $32.8M | 2.98% | 1.9M | Hold |
| 10 | TXG | 10X GENOMICS INC | $8.4M | 0.76% | 217,834 | Hold |
| 11 | BOLD | BOUNDLESS BIO INC | $6.7M | 0.61% | 2.7M | New |
| 12 | GOSS | GOSSAMER BIO INC | $1.3M | 0.12% | 8.1M | Hold |
| 13 | QTTB | Q32 BIO INC | $0 | 0.00% | 0 | Exited |
Source: SEC Form 13F filings · as of 2026-06-30